Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.

For men with localized prostate cancer, xxxx demonstrated that adding short-term Androgen deprivation therapy (ADT) to radiotherapy (RT) improved the primary endpoint of overall-survival (OS) and also improved disease-specific-mortality (DSM), biochemical-failure (BF), local-progression (LP) and freedom from distant-metastases (DM).